Convergence of nanotechnology and CRISPR-based diagnostics

Area of Science:

• Biotechnology
• Nanotechnology
• Molecular Diagnostics

Background:

• Clustered regularly interspaced short palindromic repeats (CRISPR) technology is pivotal in genome engineering and therapeutics.
• CRISPR-based assays demonstrate significant potential for diagnosing infectious and non-communicable diseases due to their sensitivity and selectivity.
• Field-deployable CRISPR methods offer accessible nucleic acid detection capabilities.

Purpose of the Study:

• To evaluate recent nanotechnologies and nanomaterials engineered to interface with CRISPR systems.
• To explore how these nanoscale integrations can realize the full diagnostic potential of CRISPR technology.
• To assess biomolecules, nanoparticles, and integrated detection platforms for CRISPR-based diagnostics.

Main Methods:

• Review and assessment of existing nanotechnologies and nanomaterials interfacing with CRISPR.
• Analysis of biomolecules (enzymes, oligonucleotides) and synthetic nanoparticles used in CRISPR assays.
• Evaluation of detection platforms integrating nanotechnologies for CRISPR diagnostics.

Main Results:

• Nanomaterials and nanotechnologies significantly enhance the sensitivity and selectivity of CRISPR-based nucleic acid detection.
• Integration of diverse nanomaterials offers innovative approaches for CRISPR diagnostic platforms.
• Various biomolecules and nanoparticles are key components in advancing CRISPR diagnostic capabilities.

Conclusions:

• Nanotechnology integration is crucial for unlocking the full potential of CRISPR for sensitive and selective nucleic acid detection.
• CRISPR-based diagnostics, enhanced by nanotechnology, hold substantial promise for clinical applications in disease identification.
• Future directions include non-nucleic acid targets, pre-amplification-free detection, wearable devices, and AI integration.